A research team at Florida Atlantic University (FAU)’s College of Engineering and Computer Science in the US has created a new technique to predict if a Covid-19 trial will conclude or cease.

The method leverages machine learning algorithms and ensemble learning.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to the research, features are available for clinical trial reports, including features to model trial management, information and design, eligibility, keywords and drugs among others.

In addition, the study demonstrated that computational techniques could provide effective models to help distinguish between completed and cessation Covid-19 trials.

These models can further predict trial status with acceptable precision, the researchers noted.

Randomised trials are conducted to gather safety and efficacy data and to understand the new and evolving SARS-CoV-2 virus.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

As of 15 July 2021, approximately 6,180 Covid-19 trials have been registered via ClinicalTrials.gov, the US registry for both private and public-funded trials performed globally.

Information on which trials will be successful is considered vital.

As Covid-19 is a relatively new disease, a small number of trials have been formally terminated, and hence the FAU team considered terminated, withdrawn and suspended studies as cessation trials.

FAU department of computer and electrical engineering and computer science professor Xingquan Hill said: “The main purpose of our research was to predict whether a Covid-19 clinical trial will be completed or terminated, withdrawn or suspended.

“If we can predict the likelihood of whether a trial might be terminated or not down the road, it will help stakeholders better plan their resources and procedures.”

The research team gathered 4,441 Covid-19 trials from ClinicalTrials.gov and created statistics, keyword, drug and embedding features. A total of 693-dimensional features were designed to signify each trial.

It was observed that keyword features obtained from the medical subject heading terms of the trial reports were the most insightful to predict Covid-19 studies.

The National Science Foundation award funded the research.

 

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact